April 30th 2024
The HCPLive Endocrinology month in review for April 2024 spotlights SURMOUNT-OSA, STEP HFpEF DM, new ACP guidelines for T2D, and more!
Diabetes Dialogue: Breaking Down the Medtronic 780G Approval, with Robert Vigersky, MD
May 12th 2023In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.
Depression or Anxiety During Pregnancy Could Increase Type 1 Diabetes Risk for Offspring
May 4th 2023An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.
Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D
May 3rd 2023In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.
Clinical Data on Finerenone in Diabetic Kidney Disease
April 27th 2023Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Control-IQ Technology Linked to Improved Glycemic Control, Regardless of Patient Age
April 20th 2023A meta-analysis of trials examining use of the t:slim X2 insulin pump with Control-IQ technology, results of the study indicate use of the hybrid closed loop technology was associated with improvements in glycemic control, regardless of patient age, race, or previous CGM use.
Diabetes Dialogue: News on Abbott Readers & CMS Expansion of CGM Availability
April 19th 2023Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.
Study: Insulin Shelf Life Could Be 4 Times Longer than Previously Reported
April 12th 2023A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.
FDA Issues Class I Recall of Abbott FreeStyle Readers for Risk of Overheating, Fire
April 6th 2023Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.